Mode
Text Size
Log in / Sign up

Polygenic risk scores improve identification of rare variant carriers in idiopathic pulmonary fibrosis patients.

Polygenic risk scores improve identification of rare variant carriers in idiopathic pulmonary fibros…
Photo by Prasesh Shiwakoti (Lomash) / Unsplash
Key Takeaway
Consider that polygenic risk scores may modestly improve rare variant carrier identification in IPF, but evidence is observational and not causal.

This observational cohort study analyzed IPF patients from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR; n=888) and the UK PROFILE cohort (n=472 for validation). The study compared polygenic risk scores (PRS) for IPF—whole-genome PRS using C+T and SBayesRC methods, and a Sentinel-PRS from 19 known variants—against a clinical model based on patient history to identify carriers of rare qualifying variants (QVs) in genes linked to monogenic pulmonary fibrosis.

Main results showed inverse associations between all PRS types and QV carrier status. The whole-genome PRS using C+T had an odds ratio of 0.65 (95% CI 0.53-0.79), the SBayesRC method had an OR of 0.71 (95% CI 0.59-0.86), and the Sentinel-PRS had an OR of 0.77 (95% CI 0.63-0.94). Adding PRS to the clinical model improved discriminatory performance: the AUC increased from 0.62 to 0.68 for C+T (DeLong test p=9.54x10-4) and from 0.62 to 0.66 for SBayesRC (p=0.02).

Reclassification analysis showed correct reclassification of QV carriers in 22.8% with WG-PRSC+T, 20.8% with Sentinel-PRS, and 16.7% with WG-PRSSBayesRC. Safety data were not reported, as this was a registry-based cohort study. Key limitations include moderate overall discriminatory power and the observational design, which does not establish causation.

Practice relevance suggests that incorporating IPF-PRS into clinical models may enhance identification of rare variant carriers, potentially aiding decision-making for variant discovery. However, findings are associative and should not be overinterpreted.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background: Idiopathic pulmonary fibrosis (IPF) is a rare disease with a poor prognosis. Disease risk involves rare and common genetic variants. However, an inverse association have been described between them. Accordingly, IPF patients with a higher polygenic risk score (PRS) for IPF are less likely to carry rare deleterious variants and vice versa. Here, we evaluate weather PRS of IPF could serve as an additional criterion to patient prioritisation for rare variant discovery. Methods: We identified carriers based on the presence of rare qualifying variants (QVs) in genes linked to monogenic forms of pulmonary fibrosis in 888 IPF patients from the Pulmonary Fibrosis Foundation Patient Registry (PFF-PR). Genome-wide association study (GWAS) summary statistics from independent cohorts were used to construct a whole-genome PRS (WG-PRS) using a clumping and thresholding method (C+T) and a Bayesian method (SBayesRC). PRS were also derived from 19 known common sentinel IPF variants (Sentinel-PRS). Logistic regression models were used to evaluate associations between PRS and carrier status. Discriminatory performance was evaluated using area under the curve (AUC) analysis, and comparisons were made with DeLong test. Validation was performed in 472 IPF individuals from the UK PROFILE cohort. Results: IPF-PRS were strongly associated with the QVs carrier status: Odds Ratio [OR] 0.65 (95% Confidence Interval [CI] 0.53-0.79) for WG-PRSC+T, OR 0.71 (95% CI 0.59-0.86) for WG-PRSSBayesRC, and OR 0.77 (95% CI 0.63-0.94) for Sentinel-PRS. Adding WG-PRS to the patient personal clinical history improved the prediction of QVs carriers: AUC=0.62 for the clinical model, AUC=0.68 for WG-PRSC+T (DeLong test, p=9.54x10-4) and AUC=0.66 for WG-PRSSBayesRC (DeLong test, p=0.02). Adding of IPF-PRS to clinical variables correctly reclassified 22.8% of carriers when using WG-PRSC+T, 20.8% when using Sentinel-PRS, and 16.7% for WG-PRSSBayesRC. WG-PRSSBayesRC and the Sentinel-PRS also demonstrated improved prediction of QVs carriers in telomere-related genes in PROFILE. Conclusions: Incorporating IPF-PRS into a model based on the patient clinical history improves the identification of QVs carriers. Although the overall discriminatory power was moderate, these findings raise de the possibility of using WG-PRS as useful criterion for rare variant discovery in patients with IPF and enhance decision-making.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.